- Moderna is testing a 50-microgram dose of its vaccine in previously vaccinated individuals.
- It found the booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1, two variants that have since spread to other countries, including the U.S.
A booster shot of Moderna’s Covid-19 vaccine generated a promising immune response against the B.1.351 and P.1 variants first identified in South Africa and Brazil, respectively, the company announced Wednesday, citing early data from an ongoing clinical trial.
